Clinical Trial Update: HAIC+Adebrelimab+Lenvatinib for Conversion Treatment of Potentially Resectable, Locally Advanced Biliary Tract Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating HAIC plus Adebrelimab and Lenvatinib as conversion therapy for potentially resectable, locally advanced biliary tract cancer; the study…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Biliary Tract Cancer

Drugs mentioned

• Adebrelimab (adebrelimab)
• Lenvatinib (lenvatinib)

Snippet

Sponsor: Harbin Medical University | Conditions: Biliary Tract Cancer | Phase 2 | Status: NOT_YET_RECRUITING